Santini, Valeria

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Fenaux, P., Mufti, G. J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., et al. (2009) · The Lancet Oncology

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 2,663

Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

Fenaux, P., Mufti, G. J., Hellström-Lindberg, E., Santini, V., Gattermann, N., Germing, U., Sanz, G., List, A. F., Gore, S., Seymour, J. F., et al. (2010) · Journal of Clinical Oncology

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 961

Molecular International Prognostic Scoring System for Myelodysplastic Syndromes

Bernard, E., Tuechler, H., Greenberg, P. L., Hasserjian, R. P., Arango Ossa, J. E., Nannya, Y., Devlin, S. M., Creignou, M., Pinel, P., Monnier, L., et al. (2022) · NEJM Evidence

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 867

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

Bernard, E., Nannya, Y., Hasserjian, R. P., Devlin, S. M., Tuechler, H., Medina-Martinez, J. S., Yoshizato, T., Shiozawa, Y., Saiki, R., Malcovati, L., et al. (2020) · Nature Medicine

Acute Myeloid Leukemia ResearchCancer-related Molecular Pathways

Cited by 648

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups

for the International Working Group for MDS Molecular Prognostic Committee, Haase, D., Stevenson, K. E., Neuberg, D., Maciejewski, J. P., Nazha, A., Sekeres, M. A., Ebert, B. L., Garcia-Manero, G., Haferlach, C., et al. (2019) · Leukemia

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 259

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML

Adès, L., Girshova, L., Doronin, V. A., Díez-Campelo, M., Valcárcel, D., Kambhampati, S., Viniou, N.-A., Woszczyk, D., De Paz Arias, R., Symeonidis, A., et al. (2022) · Blood Advances

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 130

A variant erythroferrone disrupts iron homeostasis in SF3B1 -mutated myelodysplastic syndrome

Bondu, S., Alary, A.-S., Lefèvre, C., Houy, A., Jung, G., Lefebvre, T., Rombaut, D., Boussaid, I., Bousta, A., Guillonneau, F., et al. (2019) · Science Translational Medicine

Acute Myeloid Leukemia ResearchIron Metabolism and Disorders

Cited by 85

Anemia as the Main Manifestation of Myelodysplastic Syndromes

Santini, V. (2015) · Seminars in Hematology

Acute Myeloid Leukemia ResearchErythropoietin and Anemia Treatment

Cited by 52

Targeting the EIF2AK1 Signaling Pathway Rescues Red Blood Cell Production in SF3B1 -Mutant Myelodysplastic Syndromes With Ringed Sideroblasts

Adema, V., Ma, F., Kanagal-Shamanna, R., Thongon, N., Montalban-Bravo, G., Yang, H., Peslak, S. A., Wang, F., Acha, P., Sole, F., et al. (2022) · Blood Cancer Discovery

Acute Myeloid Leukemia ResearchRNA Research and Splicing

Cited by 20